2. Search Result
Search Result
Results for "

bEnd.3

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

2

Natural
Products

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-171306
    MK16

    		Liposome Others
    MK16 is a lipid material that can be used to construct blood-brain barrier penetrable lipid nanoparticles for mRNA delivery. MK16 facilitates blood-brain barrier crossing via γ-secretase-mediated and caveolae-mediated transcytosis. MK16 can be used for drug delivery research .
    MK16
  • HY-173591
    T0080

    		Formyl Peptide Receptor (FPR) Apoptosis Cardiovascular Disease Neurological Disease Inflammation/Immunology
    T0080 is a central nervous system-penetrant FPR1 inhibitor. By functionally blocking the FPR1 signaling pathway, T0080 effectively reduces neutrophil infiltration into ischemic brain tissue and maintains the integrity of the blood-brain barrier. T0080 alleviates tPA-associated hemorrhagic transformation, inhibits demyelination responses and the expression of NOX2. T0080 also possesses anti-apoptotic (apoptosis) and anti-inflammatory properties, thereby protecting myelin and reducing neurological deficits. T0080 is widely used in studies related to ischemic stroke complicated by hemorrhagic transformation after tPA thrombolysis, as well as multiple sclerosis .
    T0080
  • HY-W002199
    6:2 Fluorotelomer alcohol

    6:2 FTOH; 1H,1H,2H,2H-Perfluoro-1-octanol; 2-(Perfluorohexyl)ethanol

    		 Bacterial Apoptosis ERK TNF Receptor Infection Neurological Disease
    6:2 Fluorotelomer alcohol (6:2 FTOH) is an orally active, blood-brain barrier-permeable modulator of cyclin D1 and ETS1. 6:2 Fluorotelomer alcohol downregulates cyclin D1 expression, upregulates ETS1 via the TNF-α/ERK 1/2 pathway, impairs mitochondrial membrane potential and respiratory function, increases reactive oxygen species levels, disrupts calcium homeostasis and activates endoplasmic reticulum stress markers, and induces cell proliferation inhibition and endothelial-mesenchymal transition. Furthermore, 6:2 Fluorotelomer alcohol induces morphological abnormalities in zebrafish embryos and liver developmental damage, while disrupting the brain immune microenvironment in mice, causing systemic toxicity and delayed pup maturation in CD-1 mice. 6:2 Fluorotelomer alcohol also induces cortical neuron apoptosis, glial cell activation, synaptic abnormalities, colonic barrier damage, intestinal dysbiosis and autism spectrum disorder-like symptoms in mice. 6:2 Fluorotelomer alcohol shows no mutagenic, clastogenic, primary skin/eye irritation or skin sensitizing effects, exhibits no selective reproductive toxicity in CD-1 mice, and is classified as GHS Category 4 for acute oral toxicity. 6:2 Fluorotelomer alcohol can be used in studies of neurodevelopmental disorders and autism spectrum disorders [3] .
    6:2 Fluorotelomer alcohol
  • HY-N0434
    Astragaloside III
    2 Publications Verification

    		 C-type Lectin-like Receptors (CTLRs) Apoptosis Dengue Virus Infection Cancer
    Astragaloside III is a triterpenoid saponin. Astragaloside III can be extracted from Astragalus root. Astragaloside III increases NKG2D and induces TACE phosphorylation. Astragaloside III induces Apoptosis. Astragaloside III has antiviral activity against dengue serotypes 1 and 3. Astragaloside III has anticancer activity against breast and colon cancer [3] .
    Astragaloside III
  • HY-124314
    LEI-106

    		MAGL DAGL Metabolic Disease
    LEI-106 is a dual ABHD6 and DAGL-α inhibitor, with a Ki of 0.8 μM for ABHD6, and an IC50 of 18 nM and a Ki of 0.7 μM for DAGL-α. LEI-106 blocks the synthesis of 2-arachidonoylglycerol, reduces the level of endothelial cell-derived 2-arachidonoylglycerol, without altering the levels of cannabinoids and diacylglycerol. LEI-106 is applicable to research related to diet-induced obesity and metabolic syndrome .
    LEI-106
  • HY-RS01469
    BEND3 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    BEND3 Human Pre-designed siRNA Set A contains three designed siRNAs for BEND3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    BEND3 Human Pre-designed siRNA Set A
    BEND3 Human Pre-designed siRNA Set A
  • HY-141436
    Sucrosofate potassium

    Sucrose octasulfate potassium

    		 MMP Biochemical Assay Reagents Cardiovascular Disease Metabolic Disease
    Sucrosofate potassium (Sucrose octasulfate potassium) is a wound healing promoter. Sucrosofate potassium inhibits MMP, promotes angiogenesis and improves microcirculation. Sucrosofate potassium causes mild skin irritation. Sucrosofate potassium can be used to prepare p (MMA-co-AM)/PVA@PSO hydrogels. Sucrosofate potassium is applicable to research related to diabetic wounds .
    Sucrosofate potassium
  • HY-N0434R
    Astragaloside III (Standard)

    		Reference Standards C-type Lectin-like Receptors (CTLRs) Apoptosis Dengue Virus Infection Cancer
    Astragaloside III (Standard) is the analytical standard of Astragaloside III (HY-N0434). This product is intended for research and analytical applications. Astragaloside III is a triterpenoid saponin. Astragaloside III can be extracted from Astragalus root. Astragaloside III increases NKG2D and induces TACE phosphorylation. Astragaloside III induces Apoptosis. Astragaloside III has antiviral activity against dengue serotypes 1 and 3. Astragaloside III has anticancer activity against breast and colon cancer [3] .
    Astragaloside III (Standard)
  • HY-182290
    AChE/BChE-IN-36

    		Cholinesterase (ChE) Neurological Disease
    AChE/BChE-IN-36 is a dual acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitor with blood-brain barrier permeability. AChE/BChE-IN-36 mediates blood-brain barrier transport through specific interactions with choline transporters. AChE/BChE-IN-36 can be used for the research of Alzheimer's disease .
    AChE/BChE-IN-36
  • HY-182254
    AChE/BChE-IN-35

    		Cholinesterase (ChE) Neurological Disease
    AChE/BChE-IN-35, Tacrine (HY-111338) derivative, is a brain-penetrant dual AChE/BChE inhibitor with an Electric Eel AChE IC50 of 123.66 nM, human AChE IC50 of 122.34 nM, and equine BChE IC50 of 488.00 nM. AChE/BChE-IN-35 undergoes LAT1-mediated active transport across cell membranes. AChE/BChE-IN-35 exhibits enhanced brain exposure with slower brain tissue elimination. AChE/BChE-IN-35 can be used for the research of alzheimer's disease .
    AChE/BChE-IN-35

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: